EDITAS MEDICINE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
EDITAS MEDICINE, INC. (EDIT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $28.15 per share for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2019-11-12
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $28.38, a 31.75% increase year-over-year.
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $21.54, a 84.58% increase year-over-year.
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $11.67.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2019-09-30 | $28.15 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $27.84 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $28.38 10-Q · filed 2019-05-08 | ||
| 2018-09-30 | $24.88 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $24.59 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $21.54 10-Q · filed 2018-05-04 | ||
| 2017-09-30 | $13.16 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $12.02 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $11.67 10-Q · filed 2017-05-15 | ||
| 2016-09-30 | $9.71 10-Q · filed 2016-11-09 | ||
| 2016-06-30 | $9.71 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |